Trials / Completed
CompletedNCT02337530
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Canadian Cancer Trials Group · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out what effects a new drug, selumetinib, has on lung cancer when receiving standard chemotherapy with pemetrexed and platinum-based chemotherapy.
Detailed description
This research is being done to see whether selumetinib improves the results of standard chemotherapy. The standard or usual treatment for this disease is treatment with chemotherapy alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selumetinib | |
| DRUG | Pemetrexed | |
| DRUG | Cisplatin | |
| DRUG | Carboplatin |
Timeline
- Start date
- 2015-05-26
- Primary completion
- 2017-10-31
- Completion
- 2019-06-18
- First posted
- 2015-01-13
- Last updated
- 2024-03-21
- Results posted
- 2021-06-22
Locations
12 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02337530. Inclusion in this directory is not an endorsement.